REG - Nestle SA Nestle Holdings Inc - Nestlé divests its Palforzia business

Nestle SAAnnouncement

04/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD2569La&default-theme=true

RNS Number : 2569L  Nestle SA  04 September 2023

Nestlé Press Release

 

 

 

Vevey/Switzerland, September 4, 2023

 

 

Nestlé divests its Palforzia business

 

Nestlé announced today that is has divested Palforzia, its peanut allergy
treatment business, to Stallergenes Greer, a biopharmaceutical company which
specializes in the diagnosis and treatment of allergies. The transaction was
closed upon signing.

 

This agreement follows Nestlé's announcement last year that it would conduct
a strategic review of Palforzia. Nestlé will receive milestone payments and
ongoing royalties from Stallergenes Greer.

 

"We are confident that Stallergenes Greer will take Palforzia forward and
ensure this unique treatment supports patients around the world," said Greg
Behar, CEO of Nestlé Health Science. "At the same time, the divestiture
allows Nestlé Health Science to focus on its core strengths and key growth
drivers. "

 

There will be a customary transition period to ensure business continuity and
give patients uninterrupted access to the treatment.

 

 

 

Contacts

 

Media

 

Christoph Meier

Tel.: +41 21 924 2200

mediarelations@nestle.com (mailto:mediarelations@nestle.com)

 

Investors

 

Luca Borlini

Tel.: +41 21 924 3509

ir@nestle.com (mailto:ir@nestle.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRGUGDCUDGDGXS